Molbio Diagnostics Reports Rs 52.7 Crore Profit in Q1 Post-IPO
Molbio Diagnostics, newly listed on the stock exchange, announces a Rs 52.7 crore profit for Q1, reversing last year's losses.
In a significant turnaround, Molbio Diagnostics reported a net profit of Rs 52.74 crore for the first quarter of the current fiscal year. This marks a sharp reversal from a loss of Rs 23.94 crore in the same period last year. The diagnostics company, which recently raised approximately Rs 940 crore through an Initial Public Offering (IPO), attributes its improved financial performance to increased sales of its Truenat test kits.
Strong Performance Post-IPO
The company, which was listed on the stock exchanges on August 17, reported a total income of Rs 411.48 crore for the quarter ending June 2026. This represents a substantial increase from the Rs 100.47 crore reported in the corresponding period of the previous fiscal year. The surge in revenue is largely driven by the high demand for Molbio's Truenat test kits, which saw volumes grow to 62.4 lakh units, up from 7.90 lakh units a year ago.
Truenat Test Kits Drive Growth
Truenat, a point-of-care diagnostic tool designed to detect a wide range of infectious diseases with speed and accuracy, has been a critical driver of this growth. The company's ability to capitalize on this demand has played a pivotal role in its financial recovery and growth trajectory.
Sriram Natarajan, Executive Director and CEO of Molbio Diagnostics, expressed optimism about the company's future, stating, "FY27 is a milestone year for Molbio, marking our transition to a listed company... we have begun the year on a strong note, with healthy growth across both revenue and profitability in Q1."
Future Outlook
The positive financial results come at a crucial time for Molbio Diagnostics, as it seeks to solidify its position in the diagnostics market following its recent IPO. The company's focus on expanding the reach and capabilities of its Truenat technology is expected to continue fueling growth.
As Molbio Diagnostics navigates its first year as a publicly listed company, maintaining the momentum of its Q1 performance will be key to its long-term success in the competitive diagnostics sector.